<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>During 1991-94 we treated 51 patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemias</z:mpath> and 3 patients with a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> of refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess of blasts in transformation </plain></SENT>
<SENT sid="1" pm="."><plain>The patients received <z:chebi fb="0" ids="45924">trimethoprim</z:chebi>-sulphamethoxazole (<z:chebi fb="5" ids="46324,9533">TMP</z:chebi>-<z:chebi fb="0" ids="9332">SMX</z:chebi>) 1,920 mg daily as a prophylaxis of <z:e sem="disease" ids="C0851886" disease_type="Disease or Syndrome" abbrv="">Pneumocystis carinii infections</z:e> and selective decontamination of gastrointestinal tract </plain></SENT>
<SENT sid="2" pm="."><plain>The majority of patients received <z:chebi fb="5" ids="46324,9533">TMP</z:chebi>-<z:chebi fb="0" ids="9332">SMX</z:chebi> in their first course of chemotherapy with <z:chebi fb="0" ids="41977">daunorubicin</z:chebi> and <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Only one of the 18 patients without <z:chebi fb="5" ids="46324,9533">TMP</z:chebi>-<z:chebi fb="0" ids="9332">SMX</z:chebi> prophylaxis during the first course of chemotherapy developed Pneumocystis carinii <z:hpo ids='HP_0002090'>pneumonia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>That <z:hpo ids='HP_0002090'>pneumonia</z:hpo> was successfully treated by intravenous administration of <z:chebi fb="5" ids="46324,9533">TMP</z:chebi>-<z:chebi fb="0" ids="9332">SMX</z:chebi> 1920 mg four times a day </plain></SENT>
<SENT sid="5" pm="."><plain>No other <z:e sem="disease" ids="C0851886" disease_type="Disease or Syndrome" abbrv="">Pneumocystis carinii infection</z:e> was encountered in <z:hpo ids='HP_0000001'>all</z:hpo> other patients during their clinical follow up or in autopsy material of expired patients </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="5" ids="46324,9533">TMP</z:chebi>-<z:chebi fb="0" ids="9332">SMX</z:chebi> prophylaxis had to be interrupted in 11 patients due to their suspicious <z:e sem="disease" ids="C0863090" disease_type="Disease or Syndrome" abbrv="">allergic skin reactions</z:e>, however, <z:chebi fb="5" ids="46324,9533">TMP</z:chebi>-<z:chebi fb="0" ids="9332">SMX</z:chebi> was readministered in <z:hpo ids='HP_0000001'>all</z:hpo> without any skin changes attributable to <z:chebi fb="5" ids="46324,9533">TMP</z:chebi>-<z:chebi fb="0" ids="9332">SMX</z:chebi> during next cycles of chemotherapy </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="5" ids="46324,9533">TMP</z:chebi>-<z:chebi fb="0" ids="9332">SMX</z:chebi> in a given daily dose of 1,920 mg seems to be a successful prophylaxis of <z:e sem="disease" ids="C0851886" disease_type="Disease or Syndrome" abbrv="">Pneumocystis carinii infections</z:e> in patients with malignant diseases of hematopoiesis </plain></SENT>
</text></document>